Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma.
Standard
Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma. / Lange, Tobias; Nentwich, Michael; Lueth, Manuel; Yekebas, Emre F.; Schumacher, Udo.
In: CANCER LETT, Vol. 308, No. 1, 1, 2011, p. 54-61.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma.
AU - Lange, Tobias
AU - Nentwich, Michael
AU - Lueth, Manuel
AU - Yekebas, Emre F.
AU - Schumacher, Udo
PY - 2011
Y1 - 2011
N2 - HER-2/neu over-expression occurs in 10-40% of patients with esophageal adenocarcinoma. Therefore, inhibitory effects of trastuzumab on proliferation, neoangiogenesis and metastatic spread of the esophageal adenocarcinoma cell line PT1590 were investigated (subcutaneous xenograft model). PT1590 revealed an amplified copy number of c-erbB2 and HER-2/neu over-expression occured in xenograft tumors and spontaneous lung metastases. PT1590 proliferation was significantly inhibited by trastuzumab in vitro. In vivo, tumor weight, volume, microvessel density and number of lung metastases decreased significantly after three weeks of treatment. These data suggest the importance of HER-2/neu for metastatic spread in esophageal adenocarcinoma and encourages clinical trials.
AB - HER-2/neu over-expression occurs in 10-40% of patients with esophageal adenocarcinoma. Therefore, inhibitory effects of trastuzumab on proliferation, neoangiogenesis and metastatic spread of the esophageal adenocarcinoma cell line PT1590 were investigated (subcutaneous xenograft model). PT1590 revealed an amplified copy number of c-erbB2 and HER-2/neu over-expression occured in xenograft tumors and spontaneous lung metastases. PT1590 proliferation was significantly inhibited by trastuzumab in vitro. In vivo, tumor weight, volume, microvessel density and number of lung metastases decreased significantly after three weeks of treatment. These data suggest the importance of HER-2/neu for metastatic spread in esophageal adenocarcinoma and encourages clinical trials.
KW - Animals
KW - Humans
KW - Female
KW - Immunohistochemistry
KW - Mice
KW - Cell Line, Tumor
KW - Neoplasm Metastasis
KW - Gene Amplification
KW - Dose-Response Relationship, Drug
KW - Cell Growth Processes/drug effects
KW - Mice, SCID
KW - Xenograft Model Antitumor Assays
KW - Adenocarcinoma/drug therapy/genetics/pathology
KW - Angiogenesis Inhibitors/pharmacology
KW - Antibodies, Monoclonal/pharmacology
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Agents/pharmacology
KW - Esophageal Neoplasms/blood supply/drug therapy/genetics/pathology
KW - Genes, erbB-2
KW - Lung Neoplasms/drug therapy/secondary
KW - Receptor, erbB-2/antagonists & inhibitors/biosynthesis/genetics
KW - Animals
KW - Humans
KW - Female
KW - Immunohistochemistry
KW - Mice
KW - Cell Line, Tumor
KW - Neoplasm Metastasis
KW - Gene Amplification
KW - Dose-Response Relationship, Drug
KW - Cell Growth Processes/drug effects
KW - Mice, SCID
KW - Xenograft Model Antitumor Assays
KW - Adenocarcinoma/drug therapy/genetics/pathology
KW - Angiogenesis Inhibitors/pharmacology
KW - Antibodies, Monoclonal/pharmacology
KW - Antibodies, Monoclonal, Humanized
KW - Antineoplastic Agents/pharmacology
KW - Esophageal Neoplasms/blood supply/drug therapy/genetics/pathology
KW - Genes, erbB-2
KW - Lung Neoplasms/drug therapy/secondary
KW - Receptor, erbB-2/antagonists & inhibitors/biosynthesis/genetics
M3 - SCORING: Journal article
VL - 308
SP - 54
EP - 61
JO - CANCER LETT
JF - CANCER LETT
SN - 0304-3835
IS - 1
M1 - 1
ER -
